Target- |
Mechanism- |
|
|
|
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.CN |
First Approval Date17 Aug 2020 |
100 Clinical Results associated with Langzhi Group Double Pharmaceutical Co., Ltd.
0 Patents (Medical) associated with Langzhi Group Double Pharmaceutical Co., Ltd.
100 Deals associated with Langzhi Group Double Pharmaceutical Co., Ltd.
100 Translational Medicine associated with Langzhi Group Double Pharmaceutical Co., Ltd.